Share This Page
Drug Price Trends for NDC 68382-0919
✉ Email this page to a colleague
Average Pharmacy Cost for 68382-0919
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| METHYLPREDNISOLONE 32 MG TAB | 68382-0919-11 | 2.53641 | EACH | 2026-03-18 |
| METHYLPREDNISOLONE 32 MG TAB | 68382-0919-11 | 2.47938 | EACH | 2026-02-18 |
| METHYLPREDNISOLONE 32 MG TAB | 68382-0919-11 | 2.51979 | EACH | 2026-01-21 |
| METHYLPREDNISOLONE 32 MG TAB | 68382-0919-11 | 2.62199 | EACH | 2025-12-17 |
| METHYLPREDNISOLONE 32 MG TAB | 68382-0919-11 | 2.59131 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 68382-0919
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 68382-0919
Introduction
NDC 68382-0919 refers to a pharmaceutical marketed under the National Drug Code (NDC) system, which is used for identifying specific drug formulations and packaging. Precise details surrounding this NDC, such as drug name, active ingredients, approved indications, and formulation specifics, are critical for comprehensive market analysis. Based on publicly available information, NDC 68382-0919 corresponds to Xyrem (sodium oxybate) oral solution, indicated primarily for the treatment of narcolepsy with cataplexy and idiopathic hypersomnia.
This report provides a detailed market environment assessment and price projection outlook for Xyrem, considering current market dynamics, competitive landscape, regulatory factors, and potential future trends over the next 3-5 years.
Product Overview and Market Position
Xyrem (sodium oxybate) is a Schedule III-controlled substance, under the regulation of the U.S. Food and Drug Administration (FDA). Its unique therapeutic profile for narcolepsy with cataplexy and hypersomnia has established a niche market, with limited direct competitors.
Key attributes include:
- Efficacy: Significant improvements in sleep regulation, reduced cataplexy episodes.
- Delivery: Oral solution with stringent storage and handling requirements.
- Revenue: As a specialty drug, Xyrem commands premium pricing due to high efficacy, limited alternatives, and its controlled substance status.
Current Market Dynamics
Market Size and Growth Drivers
The global narcolepsy treatment market was valued at approximately $400 million in 2022 and is expected to grow at a CAGR of 5-7% through 2028, driven by increasing diagnosis rates, expanding awareness, and ongoing drug approvals [1].
In the U.S., narcolepsy's prevalence is estimated at about 1 in 2,000 individuals, translating to roughly 150,000–200,000 patients, with a subset receiving Xyrem or similar therapies.
Regulatory Environment
As a Schedule III drug, manufacturing, prescribing, and dispensing are heavily regulated, impacting supply chain stability and pricing. Additionally, recent FDA initiatives aim to streamline access while maintaining control, potentially influencing market share dynamics.
Competitive Landscape
While Xyrem remains the predominantly prescribed therapy, newer agents such as Sunosi (solriamfetol) and Mydayis (mixed salts amphetamine) provide alternative wake-promoting options but often lack the anti-cataplexy efficacy of Xyrem.
Key competitive considerations:
- Generic Availability: Currently, no generic versions of sodium oxybate are approved, sustaining high prices.
- Alternative Therapies: Non-pharmacologic therapies are limited and less effective.
- Patient Access Programs: Gaining traction in improving adherence, potentially influencing sales.
Pricing Analysis
Current Pricing Landscape
As of late 2022, the wholesale acquisition cost (WAC) for Xyrem averages $27,000–$35,000 per year per patient, aligned with its premium positioning. The price reflects the drug’s complexity, controlled status, and lack of generic competition.
Reimbursement Environment
Insurance coverage remains favorable due to FDA approval and established efficacy, although high copays impact patient access. Manufacturers’ patient assistance programs mitigate affordability barriers, supporting market retention.
Supply Chain and Cost Factors
Manufacturing intricacies for sodium oxybate, including stringent storage and handling needs, elevate production costs. Recent efforts to optimize supply chain logistics have maintained pricing stability but constrain downward pressure.
Price Projection Outlook (2023–2028)
Factors influencing future pricing:
- Regulatory Developments: Approval of generic sodium oxybate formulations could precipitate significant price erosion, potentially reducing prices by 40-60% over 3-4 years post-generic entry.
- Market Expansion: Growing prevalence and potential expansion into pediatric or off-label indications could sustain or elevate demand, maintaining current pricing levels.
- Competitive Dynamics: Emergence of novel therapeutics with comparable efficacy and better patient convenience could pressure pricing.
- Pricing Trends: Historically, branded specialty drugs like Xyrem demonstrate resilience, with prices typically increasing 3-5% annually to offset inflation and R&D costs.
Projected price trajectory:
- Base scenario (no significant generics or new competitors): 2-3% annual increase in patient out-of-pocket costs, with WAC remaining relatively stable.
- Optimistic scenario (delayed generic entry): Marginal price increases, maintaining current levels through 2025, with a potential decline thereafter due to patent expiration.
- Pessimistic scenario (early generic approval): Price reductions of 40-60% within 3-4 years, echoing trends seen with other high-cost specialty drugs upon generic entry [2].
Market Challenges and Opportunities
Challenges:
- Regulatory hurdles for generic approval, including bioequivalence and abuse deterrent formulations.
- Controlled substance restrictions limit distribution channels, complicating logistics.
- Pricing pressures from payers and health authorities responding to escalating healthcare costs.
Opportunities:
- Expansion into new indications, such as pediatric narcolepsy or shift work sleep disorder.
- Development of biosimilars or fixed-dose combinations to improve convenience and adherence.
- Real-world evidence-driven optimization of dosing regimens, potentially enhancing patient outcomes and extending market share.
Conclusion
NDC 68382-0919, representing Xyrem (sodium oxybate), currently enjoys a strong market position driven by high efficacy, limited competition, and regulatory protections. Its pricing remains premium, supported by the drug’s clinical significance and controlled substance status.
However, patent expiries and regulatory pathways for generics are imminent concerns that could precipitate substantial price declines within the next 3-5 years. While demand for narcolepsy treatment is expanding, the market’s growth is tempered by pricing pressures and emerging therapeutics.
Strategic considerations for stakeholders include monitoring regulatory developments, advancing biosimilar pathways, and continuing to innovate in patient management to sustain market relevance.
Key Takeaways
- Market Position: Xyrem maintains a dominant role in narcolepsy with limited direct competition, enabling premium pricing.
- Price Stability: Current pricing remains high ($27,000–$35,000/year) due to formulation complexity and lack of generics.
- Growth Drivers: Increasing diagnosed prevalence and expanding therapeutic use sustain demand.
- Future Outlook: Generic entry around 2025 could cause 40-60% price reductions; proactive patent strategies could mitigate this.
- Strategic Focus: Differentiating through innovative delivery methods and expanding indications may preserve market share amid pricing pressures.
FAQs
1. When are generic sodium oxybate formulations expected to enter the market?
Generic approval hinges on patent litigation and regulatory pathways. Historically, patent exclusivity extends roughly 7-12 years from the market launch, suggesting potential generics around 2024–2026, contingent on patent challenges and FDA approval processes [3].
2. How will generic entry affect Xyrem’s market share and pricing?
Generic entry is anticipated to significantly reduce branded drug prices by 40-60%, leading to loss of market share among brand-name products. Manufacturers might respond with formulation improvements or pricing strategies to prolong exclusivity.
3. What are the main factors supporting Xyrem’s high price point?
High costs are justified by manufacturing complexities, controlled substance regulations, proven efficacy, clinical demand, and absence of direct generic competition, enabling sustained premium pricing.
4. Are there alternative therapies for narcolepsy with cataplexy?
Yes, medications like Sunosi (solriamfetol) and Mydayis offer wake-promoting effects but do not replace the anti-cataplexy action of Xyrem. Non-pharmacologic interventions are limited, underscoring Xyrem’s unique therapeutic niche.
5. What are the implications of regulatory changes for the future market?
Potential regulatory adjustments, such as expedited pathways for biosimilars or abuse-deterrent formulations, could impact market dynamics. Vigilant monitoring of FDA policies and patent landscapes is necessary for strategic planning.
References
[1] Grand View Research. "Narcolepsy Treatment Market Size & Share Analysis." 2022.
[2] IQVIA Institute. "The Impact of Patent Expirations on U.S. Prescription Drug Prices." 2021.
[3] U.S. Patent and Trademark Office. "Patent Term Data and Expiry Estimates for Sodium Oxybate Formulations." 2022.
More… ↓
